nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—melanoma	0.374	0.703	CbGaD
Mesalazine—PTGS2—melanoma	0.158	0.297	CbGaD
Mesalazine—PPARG—dermis—melanoma	0.0077	0.118	CbGeAlD
Mesalazine—PPARG—leg—melanoma	0.00508	0.078	CbGeAlD
Mesalazine—PPARG—hindlimb—melanoma	0.00454	0.0697	CbGeAlD
Mesalazine—PPARG—appendage—melanoma	0.00389	0.0598	CbGeAlD
Mesalazine—MPO—endothelium—melanoma	0.00265	0.0407	CbGeAlD
Mesalazine—PTGS2—leg—melanoma	0.0026	0.0399	CbGeAlD
Mesalazine—MPO—blood vessel—melanoma	0.00244	0.0375	CbGeAlD
Mesalazine—CHUK—skin of body—melanoma	0.00237	0.0364	CbGeAlD
Mesalazine—PPARG—endothelium—melanoma	0.00235	0.0361	CbGeAlD
Mesalazine—PTGS2—hindlimb—melanoma	0.00232	0.0356	CbGeAlD
Mesalazine—PPARG—blood vessel—melanoma	0.00217	0.0333	CbGeAlD
Mesalazine—PTGS2—appendage—melanoma	0.00199	0.0305	CbGeAlD
Mesalazine—PTGS2—skin epidermis—melanoma	0.00166	0.0254	CbGeAlD
Mesalazine—IKBKB—skin of body—melanoma	0.00161	0.0248	CbGeAlD
Mesalazine—PPARG—neck—melanoma	0.00155	0.0238	CbGeAlD
Mesalazine—CHUK—head—melanoma	0.00155	0.0238	CbGeAlD
Mesalazine—IKBKB—mammalian vulva—melanoma	0.00147	0.0226	CbGeAlD
Mesalazine—Olsalazine—IFNG—melanoma	0.00146	0.359	CrCbGaD
Mesalazine—PTGS1—endothelium—melanoma	0.00126	0.0193	CbGeAlD
Mesalazine—PTGS2—endothelium—melanoma	0.0012	0.0184	CbGeAlD
Mesalazine—PTGS1—blood vessel—melanoma	0.00116	0.0178	CbGeAlD
Mesalazine—MPO—skin of body—melanoma	0.00113	0.0174	CbGeAlD
Mesalazine—PTGS2—blood vessel—melanoma	0.00111	0.017	CbGeAlD
Mesalazine—CHUK—lymph node—melanoma	0.00108	0.0166	CbGeAlD
Mesalazine—IKBKB—head—melanoma	0.00105	0.0162	CbGeAlD
Mesalazine—PPARG—skin of body—melanoma	0.001	0.0154	CbGeAlD
Mesalazine—PPARG—mammalian vulva—melanoma	0.000915	0.014	CbGeAlD
Mesalazine—ALOX5—head—melanoma	0.000872	0.0134	CbGeAlD
Mesalazine—MPO—head—melanoma	0.000738	0.0113	CbGeAlD
Mesalazine—IKBKB—lymph node—melanoma	0.000737	0.0113	CbGeAlD
Mesalazine—Olsalazine—PPARG—melanoma	0.000687	0.169	CrCbGaD
Mesalazine—PPARG—head—melanoma	0.000655	0.0101	CbGeAlD
Mesalazine—ALOX5—lymph node—melanoma	0.000611	0.00937	CbGeAlD
Mesalazine—PTGS1—skin of body—melanoma	0.000537	0.00824	CbGeAlD
Mesalazine—MPO—lymph node—melanoma	0.000517	0.00793	CbGeAlD
Mesalazine—PTGS2—skin of body—melanoma	0.000513	0.00787	CbGeAlD
Mesalazine—PTGS1—mammalian vulva—melanoma	0.000489	0.00751	CbGeAlD
Mesalazine—PPARG—lymph node—melanoma	0.000459	0.00704	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—melanoma	0.000423	0.104	CrCbGaD
Mesalazine—PTGS1—head—melanoma	0.00035	0.00537	CbGeAlD
Mesalazine—PTGS2—head—melanoma	0.000335	0.00514	CbGeAlD
Mesalazine—Olsalazine—PTGS2—melanoma	0.00029	0.0714	CrCbGaD
Mesalazine—Diflunisal—PTGS2—melanoma	0.000273	0.0671	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—melanoma	0.000273	0.0671	CrCbGaD
Mesalazine—PTGS1—lymph node—melanoma	0.000245	0.00376	CbGeAlD
Mesalazine—Diflunisal—ALB—melanoma	0.000243	0.0598	CrCbGaD
Mesalazine—PTGS2—lymph node—melanoma	0.000234	0.0036	CbGeAlD
Mesalazine—Erythema—Carmustine—melanoma	0.000181	0.000951	CcSEcCtD
Mesalazine—Cough—Bleomycin—melanoma	0.000181	0.00095	CcSEcCtD
Mesalazine—Chills—Temozolomide—melanoma	0.000181	0.000947	CcSEcCtD
Mesalazine—Ill-defined disorder—Dactinomycin—melanoma	0.00018	0.000942	CcSEcCtD
Mesalazine—Anaemia—Dactinomycin—melanoma	0.000179	0.000939	CcSEcCtD
Mesalazine—Liver function test abnormal—Docetaxel—melanoma	0.000179	0.000937	CcSEcCtD
Mesalazine—Vomiting—Vemurafenib—melanoma	0.000178	0.000933	CcSEcCtD
Mesalazine—Alopecia—Temozolomide—melanoma	0.000178	0.000933	CcSEcCtD
Mesalazine—Dry skin—Docetaxel—melanoma	0.000177	0.00093	CcSEcCtD
Mesalazine—Chest pain—Bleomycin—melanoma	0.000177	0.000927	CcSEcCtD
Mesalazine—Myalgia—Bleomycin—melanoma	0.000177	0.000927	CcSEcCtD
Mesalazine—Abdominal pain upper—Docetaxel—melanoma	0.000177	0.000927	CcSEcCtD
Mesalazine—Orthostatic hypotension—Docetaxel—melanoma	0.000177	0.000927	CcSEcCtD
Mesalazine—Rash—Vemurafenib—melanoma	0.000176	0.000925	CcSEcCtD
Mesalazine—Mental disorder—Temozolomide—melanoma	0.000176	0.000925	CcSEcCtD
Mesalazine—Dermatitis—Vemurafenib—melanoma	0.000176	0.000924	CcSEcCtD
Mesalazine—Back pain—Carmustine—melanoma	0.000175	0.00092	CcSEcCtD
Mesalazine—Headache—Vemurafenib—melanoma	0.000175	0.000919	CcSEcCtD
Mesalazine—Erythema—Temozolomide—melanoma	0.000175	0.000919	CcSEcCtD
Mesalazine—Breast disorder—Docetaxel—melanoma	0.000175	0.000917	CcSEcCtD
Mesalazine—Discomfort—Bleomycin—melanoma	0.000175	0.000916	CcSEcCtD
Mesalazine—Malaise—Dactinomycin—melanoma	0.000175	0.000916	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000174	0.000914	CcSEcCtD
Mesalazine—Cramp muscle—Docetaxel—melanoma	0.000174	0.000914	CcSEcCtD
Mesalazine—Leukopenia—Dactinomycin—melanoma	0.000173	0.000909	CcSEcCtD
Mesalazine—Nasopharyngitis—Docetaxel—melanoma	0.000173	0.000907	CcSEcCtD
Mesalazine—Dysgeusia—Temozolomide—melanoma	0.000172	0.0009	CcSEcCtD
Mesalazine—Confusional state—Bleomycin—melanoma	0.000171	0.000896	CcSEcCtD
Mesalazine—Vision blurred—Carmustine—melanoma	0.000171	0.000896	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000171	0.000895	CcSEcCtD
Mesalazine—Tremor—Carmustine—melanoma	0.00017	0.000891	CcSEcCtD
Mesalazine—Anaphylactic shock—Bleomycin—melanoma	0.000169	0.000889	CcSEcCtD
Mesalazine—Oedema—Bleomycin—melanoma	0.000169	0.000889	CcSEcCtD
Mesalazine—Back pain—Temozolomide—melanoma	0.000169	0.000889	CcSEcCtD
Mesalazine—Infection—Bleomycin—melanoma	0.000168	0.000883	CcSEcCtD
Mesalazine—Anaemia—Carmustine—melanoma	0.000168	0.000879	CcSEcCtD
Mesalazine—Dysphagia—Docetaxel—melanoma	0.000167	0.000877	CcSEcCtD
Mesalazine—Nausea—Vemurafenib—melanoma	0.000166	0.000871	CcSEcCtD
Mesalazine—Thrombocytopenia—Bleomycin—melanoma	0.000166	0.00087	CcSEcCtD
Mesalazine—Vision blurred—Temozolomide—melanoma	0.000165	0.000866	CcSEcCtD
Mesalazine—Myalgia—Dactinomycin—melanoma	0.000165	0.000865	CcSEcCtD
Mesalazine—Bronchospasm—Docetaxel—melanoma	0.000164	0.000863	CcSEcCtD
Mesalazine—Tremor—Temozolomide—melanoma	0.000164	0.000861	CcSEcCtD
Mesalazine—Discomfort—Dactinomycin—melanoma	0.000163	0.000854	CcSEcCtD
Mesalazine—Angina pectoris—Docetaxel—melanoma	0.000163	0.000854	CcSEcCtD
Mesalazine—Ill-defined disorder—Temozolomide—melanoma	0.000163	0.000852	CcSEcCtD
Mesalazine—Leukopenia—Carmustine—melanoma	0.000162	0.000851	CcSEcCtD
Mesalazine—Anaemia—Temozolomide—melanoma	0.000162	0.000849	CcSEcCtD
Mesalazine—Anorexia—Bleomycin—melanoma	0.000162	0.000847	CcSEcCtD
Mesalazine—Angioedema—Temozolomide—melanoma	0.00016	0.00084	CcSEcCtD
Mesalazine—Pancytopenia—Docetaxel—melanoma	0.000159	0.000833	CcSEcCtD
Mesalazine—Hypotension—Bleomycin—melanoma	0.000158	0.000831	CcSEcCtD
Mesalazine—Oedema—Dactinomycin—melanoma	0.000158	0.000829	CcSEcCtD
Mesalazine—Malaise—Temozolomide—melanoma	0.000158	0.000829	CcSEcCtD
Mesalazine—Vertigo—Temozolomide—melanoma	0.000157	0.000825	CcSEcCtD
Mesalazine—Infection—Dactinomycin—melanoma	0.000157	0.000824	CcSEcCtD
Mesalazine—Leukopenia—Temozolomide—melanoma	0.000157	0.000822	CcSEcCtD
Mesalazine—Hypertension—Carmustine—melanoma	0.000157	0.000821	CcSEcCtD
Mesalazine—Neutropenia—Docetaxel—melanoma	0.000156	0.00082	CcSEcCtD
Mesalazine—Palpitations—Temozolomide—melanoma	0.000155	0.000812	CcSEcCtD
Mesalazine—Thrombocytopenia—Dactinomycin—melanoma	0.000155	0.000812	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Bleomycin—melanoma	0.000154	0.00081	CcSEcCtD
Mesalazine—Myalgia—Carmustine—melanoma	0.000154	0.000809	CcSEcCtD
Mesalazine—Chest pain—Carmustine—melanoma	0.000154	0.000809	CcSEcCtD
Mesalazine—Anxiety—Carmustine—melanoma	0.000154	0.000807	CcSEcCtD
Mesalazine—Cough—Temozolomide—melanoma	0.000153	0.000802	CcSEcCtD
Mesalazine—Paraesthesia—Bleomycin—melanoma	0.000152	0.000798	CcSEcCtD
Mesalazine—Weight increased—Docetaxel—melanoma	0.000152	0.000798	CcSEcCtD
Mesalazine—Salicylic acid—PTGS2—melanoma	0.000152	0.0373	CrCbGaD
Mesalazine—Weight decreased—Docetaxel—melanoma	0.000151	0.000793	CcSEcCtD
Mesalazine—Hypertension—Temozolomide—melanoma	0.000151	0.000793	CcSEcCtD
Mesalazine—Dyspnoea—Bleomycin—melanoma	0.000151	0.000792	CcSEcCtD
Mesalazine—Anorexia—Dactinomycin—melanoma	0.000151	0.00079	CcSEcCtD
Mesalazine—Pneumonia—Docetaxel—melanoma	0.00015	0.000786	CcSEcCtD
Mesalazine—Confusional state—Carmustine—melanoma	0.000149	0.000782	CcSEcCtD
Mesalazine—Arthralgia—Temozolomide—melanoma	0.000149	0.000782	CcSEcCtD
Mesalazine—Myalgia—Temozolomide—melanoma	0.000149	0.000782	CcSEcCtD
Mesalazine—Infestation NOS—Docetaxel—melanoma	0.000149	0.000782	CcSEcCtD
Mesalazine—Infestation—Docetaxel—melanoma	0.000149	0.000782	CcSEcCtD
Mesalazine—Anxiety—Temozolomide—melanoma	0.000149	0.000779	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000148	0.000777	CcSEcCtD
Mesalazine—Oedema—Carmustine—melanoma	0.000148	0.000776	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000148	0.000775	CcSEcCtD
Mesalazine—Discomfort—Temozolomide—melanoma	0.000147	0.000773	CcSEcCtD
Mesalazine—Decreased appetite—Bleomycin—melanoma	0.000147	0.000773	CcSEcCtD
Mesalazine—Infection—Carmustine—melanoma	0.000147	0.000771	CcSEcCtD
Mesalazine—Renal failure—Docetaxel—melanoma	0.000147	0.000769	CcSEcCtD
Mesalazine—Neuropathy peripheral—Docetaxel—melanoma	0.000146	0.000766	CcSEcCtD
Mesalazine—Dry mouth—Temozolomide—melanoma	0.000146	0.000765	CcSEcCtD
Mesalazine—Jaundice—Docetaxel—melanoma	0.000145	0.000762	CcSEcCtD
Mesalazine—Stomatitis—Docetaxel—melanoma	0.000145	0.000762	CcSEcCtD
Mesalazine—Pain—Bleomycin—melanoma	0.000145	0.00076	CcSEcCtD
Mesalazine—Conjunctivitis—Docetaxel—melanoma	0.000145	0.00076	CcSEcCtD
Mesalazine—Thrombocytopenia—Carmustine—melanoma	0.000145	0.00076	CcSEcCtD
Mesalazine—Tachycardia—Carmustine—melanoma	0.000144	0.000757	CcSEcCtD
Mesalazine—Confusional state—Temozolomide—melanoma	0.000144	0.000756	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000144	0.000755	CcSEcCtD
Mesalazine—Oedema—Temozolomide—melanoma	0.000143	0.00075	CcSEcCtD
Mesalazine—Anaphylactic shock—Temozolomide—melanoma	0.000143	0.00075	CcSEcCtD
Mesalazine—Infection—Temozolomide—melanoma	0.000142	0.000745	CcSEcCtD
Mesalazine—Anorexia—Carmustine—melanoma	0.000141	0.00074	CcSEcCtD
Mesalazine—Hepatobiliary disease—Docetaxel—melanoma	0.000141	0.000739	CcSEcCtD
Mesalazine—Epistaxis—Docetaxel—melanoma	0.000141	0.000737	CcSEcCtD
Mesalazine—Nervous system disorder—Temozolomide—melanoma	0.00014	0.000735	CcSEcCtD
Mesalazine—Thrombocytopenia—Temozolomide—melanoma	0.00014	0.000734	CcSEcCtD
Mesalazine—Feeling abnormal—Bleomycin—melanoma	0.00014	0.000733	CcSEcCtD
Mesalazine—Agranulocytosis—Docetaxel—melanoma	0.000139	0.00073	CcSEcCtD
Mesalazine—Skin disorder—Temozolomide—melanoma	0.000139	0.000728	CcSEcCtD
Mesalazine—Hypotension—Carmustine—melanoma	0.000138	0.000725	CcSEcCtD
Mesalazine—Hyperhidrosis—Temozolomide—melanoma	0.000138	0.000725	CcSEcCtD
Mesalazine—Decreased appetite—Dactinomycin—melanoma	0.000137	0.000721	CcSEcCtD
Mesalazine—Fatigue—Dactinomycin—melanoma	0.000136	0.000715	CcSEcCtD
Mesalazine—Anorexia—Temozolomide—melanoma	0.000136	0.000715	CcSEcCtD
Mesalazine—Pain—Dactinomycin—melanoma	0.000135	0.000709	CcSEcCtD
Mesalazine—Salicylic acid—ALB—melanoma	0.000135	0.0333	CrCbGaD
Mesalazine—Musculoskeletal discomfort—Carmustine—melanoma	0.000135	0.000707	CcSEcCtD
Mesalazine—Urticaria—Bleomycin—melanoma	0.000135	0.000706	CcSEcCtD
Mesalazine—Haemoglobin—Docetaxel—melanoma	0.000135	0.000705	CcSEcCtD
Mesalazine—Rhinitis—Docetaxel—melanoma	0.000134	0.000704	CcSEcCtD
Mesalazine—Body temperature increased—Bleomycin—melanoma	0.000134	0.000703	CcSEcCtD
Mesalazine—Haemorrhage—Docetaxel—melanoma	0.000134	0.000702	CcSEcCtD
Mesalazine—Hepatitis—Docetaxel—melanoma	0.000134	0.000702	CcSEcCtD
Mesalazine—Insomnia—Carmustine—melanoma	0.000134	0.000702	CcSEcCtD
Mesalazine—Paraesthesia—Carmustine—melanoma	0.000133	0.000697	CcSEcCtD
Mesalazine—Pharyngitis—Docetaxel—melanoma	0.000133	0.000697	CcSEcCtD
Mesalazine—Urinary tract disorder—Docetaxel—melanoma	0.000132	0.000693	CcSEcCtD
Mesalazine—Dyspnoea—Carmustine—melanoma	0.000132	0.000692	CcSEcCtD
Mesalazine—Oedema peripheral—Docetaxel—melanoma	0.000132	0.000691	CcSEcCtD
Mesalazine—Somnolence—Carmustine—melanoma	0.000132	0.00069	CcSEcCtD
Mesalazine—Connective tissue disorder—Docetaxel—melanoma	0.000132	0.00069	CcSEcCtD
Mesalazine—Urethral disorder—Docetaxel—melanoma	0.000131	0.000688	CcSEcCtD
Mesalazine—Feeling abnormal—Dactinomycin—melanoma	0.00013	0.000683	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Temozolomide—melanoma	0.00013	0.000683	CcSEcCtD
Mesalazine—Insomnia—Temozolomide—melanoma	0.000129	0.000678	CcSEcCtD
Mesalazine—Gastrointestinal pain—Dactinomycin—melanoma	0.000129	0.000678	CcSEcCtD
Mesalazine—Salicylic acid—ABCB1—melanoma	0.000129	0.0317	CrCbGaD
Mesalazine—Decreased appetite—Carmustine—melanoma	0.000129	0.000675	CcSEcCtD
Mesalazine—Paraesthesia—Temozolomide—melanoma	0.000128	0.000673	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Carmustine—melanoma	0.000128	0.00067	CcSEcCtD
Mesalazine—Dyspnoea—Temozolomide—melanoma	0.000127	0.000669	CcSEcCtD
Mesalazine—Somnolence—Temozolomide—melanoma	0.000127	0.000667	CcSEcCtD
Mesalazine—Erythema multiforme—Docetaxel—melanoma	0.000127	0.000664	CcSEcCtD
Mesalazine—Pain—Carmustine—melanoma	0.000127	0.000664	CcSEcCtD
Mesalazine—Constipation—Carmustine—melanoma	0.000127	0.000664	CcSEcCtD
Mesalazine—Dyspepsia—Temozolomide—melanoma	0.000126	0.00066	CcSEcCtD
Mesalazine—Eye disorder—Docetaxel—melanoma	0.000125	0.000656	CcSEcCtD
Mesalazine—Abdominal pain—Dactinomycin—melanoma	0.000125	0.000655	CcSEcCtD
Mesalazine—Body temperature increased—Dactinomycin—melanoma	0.000125	0.000655	CcSEcCtD
Mesalazine—Hypersensitivity—Bleomycin—melanoma	0.000125	0.000655	CcSEcCtD
Mesalazine—Decreased appetite—Temozolomide—melanoma	0.000124	0.000652	CcSEcCtD
Mesalazine—Cardiac disorder—Docetaxel—melanoma	0.000124	0.000651	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Temozolomide—melanoma	0.000123	0.000647	CcSEcCtD
Mesalazine—Fatigue—Temozolomide—melanoma	0.000123	0.000646	CcSEcCtD
Mesalazine—Pain—Temozolomide—melanoma	0.000122	0.000641	CcSEcCtD
Mesalazine—Constipation—Temozolomide—melanoma	0.000122	0.000641	CcSEcCtD
Mesalazine—Feeling abnormal—Carmustine—melanoma	0.000122	0.000639	CcSEcCtD
Mesalazine—Asthenia—Bleomycin—melanoma	0.000122	0.000638	CcSEcCtD
Mesalazine—Angiopathy—Docetaxel—melanoma	0.000121	0.000637	CcSEcCtD
Mesalazine—Gastrointestinal pain—Carmustine—melanoma	0.000121	0.000634	CcSEcCtD
Mesalazine—Immune system disorder—Docetaxel—melanoma	0.000121	0.000634	CcSEcCtD
Mesalazine—Mediastinal disorder—Docetaxel—melanoma	0.000121	0.000633	CcSEcCtD
Mesalazine—Chills—Docetaxel—melanoma	0.00012	0.00063	CcSEcCtD
Mesalazine—Pruritus—Bleomycin—melanoma	0.00012	0.000629	CcSEcCtD
Mesalazine—Alopecia—Docetaxel—melanoma	0.000118	0.00062	CcSEcCtD
Mesalazine—Feeling abnormal—Temozolomide—melanoma	0.000118	0.000618	CcSEcCtD
Mesalazine—Mental disorder—Docetaxel—melanoma	0.000117	0.000615	CcSEcCtD
Mesalazine—Abdominal pain—Carmustine—melanoma	0.000117	0.000613	CcSEcCtD
Mesalazine—Body temperature increased—Carmustine—melanoma	0.000117	0.000613	CcSEcCtD
Mesalazine—Gastrointestinal pain—Temozolomide—melanoma	0.000117	0.000613	CcSEcCtD
Mesalazine—Erythema—Docetaxel—melanoma	0.000117	0.000611	CcSEcCtD
Mesalazine—Hypersensitivity—Dactinomycin—melanoma	0.000116	0.000611	CcSEcCtD
Mesalazine—Dysgeusia—Docetaxel—melanoma	0.000114	0.000598	CcSEcCtD
Mesalazine—Urticaria—Temozolomide—melanoma	0.000114	0.000596	CcSEcCtD
Mesalazine—Asthenia—Dactinomycin—melanoma	0.000113	0.000595	CcSEcCtD
Mesalazine—Abdominal pain—Temozolomide—melanoma	0.000113	0.000593	CcSEcCtD
Mesalazine—Body temperature increased—Temozolomide—melanoma	0.000113	0.000593	CcSEcCtD
Mesalazine—Back pain—Docetaxel—melanoma	0.000113	0.000591	CcSEcCtD
Mesalazine—Muscle spasms—Docetaxel—melanoma	0.000112	0.000587	CcSEcCtD
Mesalazine—Hypersensitivity—Carmustine—melanoma	0.000109	0.000572	CcSEcCtD
Mesalazine—Diarrhoea—Dactinomycin—melanoma	0.000108	0.000567	CcSEcCtD
Mesalazine—Vomiting—Bleomycin—melanoma	0.000108	0.000565	CcSEcCtD
Mesalazine—Anaemia—Docetaxel—melanoma	0.000108	0.000565	CcSEcCtD
Mesalazine—Rash—Bleomycin—melanoma	0.000107	0.00056	CcSEcCtD
Mesalazine—Dermatitis—Bleomycin—melanoma	0.000107	0.00056	CcSEcCtD
Mesalazine—Asthenia—Carmustine—melanoma	0.000106	0.000557	CcSEcCtD
Mesalazine—Hypersensitivity—Temozolomide—melanoma	0.000105	0.000552	CcSEcCtD
Mesalazine—Syncope—Docetaxel—melanoma	0.000104	0.000548	CcSEcCtD
Mesalazine—Leukopenia—Docetaxel—melanoma	0.000104	0.000547	CcSEcCtD
Mesalazine—Palpitations—Docetaxel—melanoma	0.000103	0.00054	CcSEcCtD
Mesalazine—Asthenia—Temozolomide—melanoma	0.000103	0.000538	CcSEcCtD
Mesalazine—Loss of consciousness—Docetaxel—melanoma	0.000102	0.000537	CcSEcCtD
Mesalazine—Cough—Docetaxel—melanoma	0.000102	0.000533	CcSEcCtD
Mesalazine—Diarrhoea—Carmustine—melanoma	0.000101	0.000531	CcSEcCtD
Mesalazine—Pruritus—Temozolomide—melanoma	0.000101	0.000531	CcSEcCtD
Mesalazine—Nausea—Bleomycin—melanoma	0.000101	0.000528	CcSEcCtD
Mesalazine—Hypertension—Docetaxel—melanoma	0.000101	0.000528	CcSEcCtD
Mesalazine—Vomiting—Dactinomycin—melanoma	0.000101	0.000527	CcSEcCtD
Mesalazine—Rash—Dactinomycin—melanoma	9.97e-05	0.000523	CcSEcCtD
Mesalazine—Chest pain—Docetaxel—melanoma	9.92e-05	0.00052	CcSEcCtD
Mesalazine—Myalgia—Docetaxel—melanoma	9.92e-05	0.00052	CcSEcCtD
Mesalazine—Arthralgia—Docetaxel—melanoma	9.92e-05	0.00052	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	9.85e-05	0.000517	CcSEcCtD
Mesalazine—Dizziness—Carmustine—melanoma	9.78e-05	0.000513	CcSEcCtD
Mesalazine—Diarrhoea—Temozolomide—melanoma	9.78e-05	0.000513	CcSEcCtD
Mesalazine—Dry mouth—Docetaxel—melanoma	9.7e-05	0.000509	CcSEcCtD
Mesalazine—Confusional state—Docetaxel—melanoma	9.59e-05	0.000503	CcSEcCtD
Mesalazine—Anaphylactic shock—Docetaxel—melanoma	9.51e-05	0.000499	CcSEcCtD
Mesalazine—Oedema—Docetaxel—melanoma	9.51e-05	0.000499	CcSEcCtD
Mesalazine—Dizziness—Temozolomide—melanoma	9.45e-05	0.000496	CcSEcCtD
Mesalazine—Infection—Docetaxel—melanoma	9.45e-05	0.000495	CcSEcCtD
Mesalazine—Vomiting—Carmustine—melanoma	9.41e-05	0.000493	CcSEcCtD
Mesalazine—Nausea—Dactinomycin—melanoma	9.39e-05	0.000492	CcSEcCtD
Mesalazine—Shock—Docetaxel—melanoma	9.35e-05	0.000491	CcSEcCtD
Mesalazine—Rash—Carmustine—melanoma	9.33e-05	0.000489	CcSEcCtD
Mesalazine—Nervous system disorder—Docetaxel—melanoma	9.32e-05	0.000489	CcSEcCtD
Mesalazine—Dermatitis—Carmustine—melanoma	9.32e-05	0.000489	CcSEcCtD
Mesalazine—Thrombocytopenia—Docetaxel—melanoma	9.31e-05	0.000488	CcSEcCtD
Mesalazine—Tachycardia—Docetaxel—melanoma	9.28e-05	0.000487	CcSEcCtD
Mesalazine—Headache—Carmustine—melanoma	9.27e-05	0.000486	CcSEcCtD
Mesalazine—Skin disorder—Docetaxel—melanoma	9.24e-05	0.000484	CcSEcCtD
Mesalazine—Vomiting—Temozolomide—melanoma	9.09e-05	0.000477	CcSEcCtD
Mesalazine—Anorexia—Docetaxel—melanoma	9.06e-05	0.000475	CcSEcCtD
Mesalazine—Rash—Temozolomide—melanoma	9.01e-05	0.000473	CcSEcCtD
Mesalazine—Dermatitis—Temozolomide—melanoma	9.01e-05	0.000472	CcSEcCtD
Mesalazine—Headache—Temozolomide—melanoma	8.96e-05	0.00047	CcSEcCtD
Mesalazine—Hypotension—Docetaxel—melanoma	8.88e-05	0.000466	CcSEcCtD
Mesalazine—Nausea—Carmustine—melanoma	8.79e-05	0.000461	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Docetaxel—melanoma	8.66e-05	0.000454	CcSEcCtD
Mesalazine—Insomnia—Docetaxel—melanoma	8.6e-05	0.000451	CcSEcCtD
Mesalazine—Paraesthesia—Docetaxel—melanoma	8.54e-05	0.000448	CcSEcCtD
Mesalazine—Nausea—Temozolomide—melanoma	8.49e-05	0.000445	CcSEcCtD
Mesalazine—Dyspnoea—Docetaxel—melanoma	8.48e-05	0.000445	CcSEcCtD
Mesalazine—Somnolence—Docetaxel—melanoma	8.45e-05	0.000443	CcSEcCtD
Mesalazine—Dyspepsia—Docetaxel—melanoma	8.37e-05	0.000439	CcSEcCtD
Mesalazine—Decreased appetite—Docetaxel—melanoma	8.27e-05	0.000433	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Docetaxel—melanoma	8.21e-05	0.000431	CcSEcCtD
Mesalazine—Fatigue—Docetaxel—melanoma	8.2e-05	0.00043	CcSEcCtD
Mesalazine—Constipation—Docetaxel—melanoma	8.13e-05	0.000426	CcSEcCtD
Mesalazine—Pain—Docetaxel—melanoma	8.13e-05	0.000426	CcSEcCtD
Mesalazine—Feeling abnormal—Docetaxel—melanoma	7.84e-05	0.000411	CcSEcCtD
Mesalazine—Gastrointestinal pain—Docetaxel—melanoma	7.78e-05	0.000408	CcSEcCtD
Mesalazine—Abdominal pain—Docetaxel—melanoma	7.52e-05	0.000394	CcSEcCtD
Mesalazine—Body temperature increased—Docetaxel—melanoma	7.52e-05	0.000394	CcSEcCtD
Mesalazine—Hypersensitivity—Docetaxel—melanoma	7.01e-05	0.000367	CcSEcCtD
Mesalazine—Asthenia—Docetaxel—melanoma	6.82e-05	0.000358	CcSEcCtD
Mesalazine—Pruritus—Docetaxel—melanoma	6.73e-05	0.000353	CcSEcCtD
Mesalazine—Diarrhoea—Docetaxel—melanoma	6.51e-05	0.000341	CcSEcCtD
Mesalazine—Dizziness—Docetaxel—melanoma	6.29e-05	0.00033	CcSEcCtD
Mesalazine—Vomiting—Docetaxel—melanoma	6.05e-05	0.000317	CcSEcCtD
Mesalazine—Rash—Docetaxel—melanoma	6e-05	0.000314	CcSEcCtD
Mesalazine—Dermatitis—Docetaxel—melanoma	5.99e-05	0.000314	CcSEcCtD
Mesalazine—Headache—Docetaxel—melanoma	5.96e-05	0.000312	CcSEcCtD
Mesalazine—Nausea—Docetaxel—melanoma	5.65e-05	0.000296	CcSEcCtD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.84e-06	3.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MDM2—melanoma	6.83e-06	3.29e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB4—melanoma	6.8e-06	3.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CSF2—melanoma	6.77e-06	3.26e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGF1—melanoma	6.77e-06	3.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—FGF2—melanoma	6.74e-06	3.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN2B—melanoma	6.74e-06	3.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—melanoma	6.74e-06	3.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP1B1—melanoma	6.69e-06	3.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—melanoma	6.68e-06	3.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TERT—melanoma	6.66e-06	3.2e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CB—melanoma	6.65e-06	3.2e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RAC1—melanoma	6.64e-06	3.19e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD4—melanoma	6.64e-06	3.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—E2F1—melanoma	6.63e-06	3.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FGF2—melanoma	6.62e-06	3.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—melanoma	6.59e-06	3.17e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PDGFRA—melanoma	6.56e-06	3.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD86—melanoma	6.52e-06	3.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ITGB3—melanoma	6.49e-06	3.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PRKCA—melanoma	6.49e-06	3.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—melanoma	6.44e-06	3.1e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PRKCA—melanoma	6.39e-06	3.08e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SPP1—melanoma	6.37e-06	3.06e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HIF1A—melanoma	6.37e-06	3.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAP2K2—melanoma	6.35e-06	3.05e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ERCC2—melanoma	6.34e-06	3.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGF1—melanoma	6.32e-06	3.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—melanoma	6.31e-06	3.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MDM2—melanoma	6.31e-06	3.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2—melanoma	6.29e-06	3.03e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CD—melanoma	6.28e-06	3.02e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1B—melanoma	6.24e-06	3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNG—melanoma	6.23e-06	3e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—melanoma	6.22e-06	2.99e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ALB—melanoma	6.2e-06	2.98e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MDM2—melanoma	6.2e-06	2.98e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—melanoma	6.18e-06	2.97e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—melanoma	6.16e-06	2.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CB—melanoma	6.14e-06	2.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD4—melanoma	6.13e-06	2.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PDGFRA—melanoma	6.12e-06	2.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—melanoma	6.11e-06	2.94e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—melanoma	6.11e-06	2.94e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KDR—melanoma	6.09e-06	2.93e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—melanoma	6.08e-06	2.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—melanoma	6.06e-06	2.92e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PRKCA—melanoma	6.06e-06	2.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—melanoma	6.04e-06	2.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CB—melanoma	6.03e-06	2.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RAC1—melanoma	6.02e-06	2.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD4—melanoma	6.02e-06	2.9e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERCC2—melanoma	6.01e-06	2.89e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAP2K2—melanoma	5.92e-06	2.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.91e-06	2.84e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CTNNB1—melanoma	5.89e-06	2.84e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FN1—melanoma	5.86e-06	2.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—melanoma	5.84e-06	2.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIF1A—melanoma	5.77e-06	2.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1B—melanoma	5.76e-06	2.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1A—melanoma	5.76e-06	2.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—melanoma	5.74e-06	2.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOTCH1—melanoma	5.74e-06	2.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NFKB1—melanoma	5.72e-06	2.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—melanoma	5.68e-06	2.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1B—melanoma	5.66e-06	2.72e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—melanoma	5.63e-06	2.71e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HLA-A—melanoma	5.63e-06	2.71e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CD80—melanoma	5.62e-06	2.7e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RAC1—melanoma	5.62e-06	2.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APC—melanoma	5.61e-06	2.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CG—melanoma	5.61e-06	2.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KIT—melanoma	5.61e-06	2.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—melanoma	5.61e-06	2.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—melanoma	5.59e-06	2.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGF—melanoma	5.54e-06	2.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—melanoma	5.54e-06	2.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KDR—melanoma	5.52e-06	2.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCB1—melanoma	5.51e-06	2.65e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CB—melanoma	5.48e-06	2.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—melanoma	5.46e-06	2.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CTNNB1—melanoma	5.44e-06	2.62e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—melanoma	5.43e-06	2.61e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—melanoma	5.39e-06	2.59e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIF1A—melanoma	5.39e-06	2.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTNNB1—melanoma	5.34e-06	2.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1A—melanoma	5.32e-06	2.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FN1—melanoma	5.31e-06	2.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—melanoma	5.3e-06	2.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—melanoma	5.27e-06	2.54e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.25e-06	2.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1A—melanoma	5.22e-06	2.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—melanoma	5.21e-06	2.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH1—melanoma	5.2e-06	2.5e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MAPK3—melanoma	5.2e-06	2.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NFKB1—melanoma	5.18e-06	2.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—melanoma	5.15e-06	2.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—melanoma	5.14e-06	2.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1—melanoma	5.14e-06	2.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—melanoma	5.13e-06	2.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CD80—melanoma	5.1e-06	2.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CG—melanoma	5.09e-06	2.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APC—melanoma	5.09e-06	2.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KIT—melanoma	5.09e-06	2.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PRKCA—melanoma	5.07e-06	2.44e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—melanoma	5.06e-06	2.43e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ERCC2—melanoma	5.03e-06	2.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGF—melanoma	5.03e-06	2.42e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CG—melanoma	5.01e-06	2.41e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAP2K1—melanoma	4.96e-06	2.39e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—melanoma	4.95e-06	2.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CD—melanoma	4.93e-06	2.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK3—melanoma	4.91e-06	2.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS2—melanoma	4.9e-06	2.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOTCH1—melanoma	4.85e-06	2.33e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—melanoma	4.83e-06	2.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—melanoma	4.78e-06	2.3e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD80—melanoma	4.75e-06	2.29e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KIT—melanoma	4.74e-06	2.28e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APC—melanoma	4.74e-06	2.28e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—melanoma	4.74e-06	2.28e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—melanoma	4.73e-06	2.28e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—melanoma	4.73e-06	2.28e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGF2—melanoma	4.72e-06	2.27e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGF—melanoma	4.69e-06	2.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK1—melanoma	4.67e-06	2.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—melanoma	4.67e-06	2.25e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—melanoma	4.66e-06	2.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1—melanoma	4.66e-06	2.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—melanoma	4.65e-06	2.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK3—melanoma	4.53e-06	2.18e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAP2K1—melanoma	4.5e-06	2.17e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CD—melanoma	4.47e-06	2.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—melanoma	4.46e-06	2.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK3—melanoma	4.45e-06	2.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MDM2—melanoma	4.42e-06	2.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—melanoma	4.41e-06	2.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—melanoma	4.41e-06	2.12e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—melanoma	4.41e-06	2.12e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CD—melanoma	4.4e-06	2.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—melanoma	4.36e-06	2.1e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALB—melanoma	4.34e-06	2.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK1—melanoma	4.31e-06	2.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—melanoma	4.31e-06	2.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CB—melanoma	4.3e-06	2.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGF2—melanoma	4.28e-06	2.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK1—melanoma	4.23e-06	2.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—melanoma	4.23e-06	2.04e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAP2K1—melanoma	4.2e-06	2.02e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CD—melanoma	4.17e-06	2.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.17e-06	2.01e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—melanoma	4.13e-06	1.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—melanoma	4.07e-06	1.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—melanoma	4.05e-06	1.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1B—melanoma	4.03e-06	1.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MDM2—melanoma	4.01e-06	1.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—melanoma	4e-06	1.92e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGF2—melanoma	3.99e-06	1.92e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CG—melanoma	3.97e-06	1.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—melanoma	3.95e-06	1.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—melanoma	3.95e-06	1.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—melanoma	3.95e-06	1.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CB—melanoma	3.9e-06	1.88e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—melanoma	3.85e-06	1.85e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CB—melanoma	3.84e-06	1.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—melanoma	3.84e-06	1.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CTNNB1—melanoma	3.81e-06	1.83e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—melanoma	3.8e-06	1.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—melanoma	3.75e-06	1.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—melanoma	3.75e-06	1.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—melanoma	3.74e-06	1.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MDM2—melanoma	3.74e-06	1.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—melanoma	3.74e-06	1.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1A—melanoma	3.72e-06	1.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—melanoma	3.71e-06	1.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NFKB1—melanoma	3.7e-06	1.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—melanoma	3.68e-06	1.77e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—melanoma	3.67e-06	1.77e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1B—melanoma	3.66e-06	1.76e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CB—melanoma	3.64e-06	1.75e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD4—melanoma	3.63e-06	1.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—melanoma	3.59e-06	1.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—melanoma	3.58e-06	1.72e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—melanoma	3.58e-06	1.72e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—melanoma	3.51e-06	1.69e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CD—melanoma	3.49e-06	1.68e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—melanoma	3.49e-06	1.68e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—melanoma	3.46e-06	1.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNB1—melanoma	3.46e-06	1.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALB—melanoma	3.45e-06	1.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1B—melanoma	3.41e-06	1.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—melanoma	3.4e-06	1.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—melanoma	3.39e-06	1.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1A—melanoma	3.38e-06	1.62e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—melanoma	3.37e-06	1.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—melanoma	3.35e-06	1.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NFKB1—melanoma	3.35e-06	1.61e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—melanoma	3.34e-06	1.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—melanoma	3.32e-06	1.6e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—melanoma	3.31e-06	1.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—melanoma	3.31e-06	1.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—melanoma	3.31e-06	1.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—melanoma	3.31e-06	1.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—melanoma	3.25e-06	1.57e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CTNNB1—melanoma	3.22e-06	1.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK3—melanoma	3.17e-06	1.53e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1A—melanoma	3.15e-06	1.52e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—melanoma	3.14e-06	1.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—melanoma	3.09e-06	1.49e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—melanoma	3.06e-06	1.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CB—melanoma	3.04e-06	1.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—melanoma	3.04e-06	1.46e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK1—melanoma	3.02e-06	1.45e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—melanoma	3.02e-06	1.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—melanoma	3.01e-06	1.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—melanoma	3e-06	1.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—melanoma	3e-06	1.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK3—melanoma	2.88e-06	1.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—melanoma	2.85e-06	1.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—melanoma	2.81e-06	1.35e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—melanoma	2.8e-06	1.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—melanoma	2.8e-06	1.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK1—melanoma	2.74e-06	1.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—melanoma	2.74e-06	1.32e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—melanoma	2.73e-06	1.31e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK3—melanoma	2.68e-06	1.29e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—melanoma	2.63e-06	1.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—melanoma	2.62e-06	1.26e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—melanoma	2.61e-06	1.26e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—melanoma	2.59e-06	1.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK1—melanoma	2.55e-06	1.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—melanoma	2.55e-06	1.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—melanoma	2.53e-06	1.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—melanoma	2.42e-06	1.17e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—melanoma	2.41e-06	1.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—melanoma	2.38e-06	1.14e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—melanoma	2.34e-06	1.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—melanoma	2.32e-06	1.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—melanoma	2.3e-06	1.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—melanoma	2.22e-06	1.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—melanoma	2.2e-06	1.06e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—melanoma	2.14e-06	1.03e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—melanoma	2.1e-06	1.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—melanoma	2.05e-06	9.87e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—melanoma	1.96e-06	9.44e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—melanoma	1.94e-06	9.34e-06	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—melanoma	1.91e-06	9.19e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—melanoma	1.86e-06	8.93e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—melanoma	1.81e-06	8.71e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—melanoma	1.52e-06	7.3e-06	CbGpPWpGaD
